Prof James P. Tam is the Director of the double-degree program in Biomedical Science and Chinese Medicine, the Founding Dean of the School of Biological Sciences and the Founding Director of Biological Research Centre at Nanyang Technological University, Singapore. He would be presenting ‘Design Strategies for Peptide and Proteins as Druggable Biologics’ at NTU’S Â SBS Symposium at BioPharma Asia Convention 2012.
He received his Ph.D. in Medicinal Chemistry from the University of Wisconsin, Madison, USA and held appointments as Associate Professor at The Rockefeller University, USA (1982-1991), Professor at Vanderbilt University, USA (1991-2004) and The Scripps Research Institute, USA (2004-2008). His research work focuses on the design and development of therapeutics, particularly orally active biologics, immunologics, anti-infectives, anti-proliferatives and synthetic vaccines. He has published more than 320 papers in these areas of research. He received the Vincent du Vigneaud Award in 1986, the Rao Makineni Award by American Peptide Society in 2003, and the Ralph F. Hirschmann Award by the American Chemical Society (ACS) in 2005 for his outstanding contributions to peptide and protein sciences. The Hirschmann Award, administered by the ACS, recognizes the highest achievements in the chemistry, biochemistry and biophysics of peptides at an international level. In addition to his scientific research, he has also been active in the peptide community. Besides serving on many editorial boards, he organizes international peptide and protein symposia and was co-founder of the past ten International Chinese Peptide Symposia. He received the Cathay Award from the Chinese Peptide Society, China in 1996. He was also honored as Honorary Professor by Peking University and Peking Union Medical College.
The following is a summary of his presentation:
Our laboratory has focused on developing peptidyl and proteinaceous therapeutic candidates. We use two platforms, aiming to develop druggable biologics that are orally bioavailable. First is a discovery platform to identify novel and ultra-stable proteinaceous natural products from microbes, venoms, and particularly from plants throughÂ herbalomics. Second is a development platform which includes design and highly efficient synthesis to engineer and to produce biological candidates for evaluation and concept validation. Our design platform includes strategies to increase potency and stability so as to render peptidyl biologics orally bioavailable.
Join us at NTU's SBS Symposium! 8 professors will be coming together to share their latest developments in the biopharmaceutical arena at this symposium co-located atÂ BioPharma Asia Convention.Â Pre-register to attend BioPharma Asia Convention today!